Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHMSA Ebglyss Prior Auth Coverage Update | OpenPaye…
    Ask Trek AI about this page
    CurrentHawaii Medical Service Association (HMSA)Policy N/A

    Ebglyss (lebrikizumab-lbkz) Coverage for Moderate-to-Severe Atopic Dermatitis

    Customize your policy alerts

    Sign up for all Hawaii Medical Service Association (HMSA) policy alerts

    Know when Hawaii Medical Service Association (HMSA) releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs HMSA prior authorization and reauthorization for Ebglyss in HMO and PPO members 12 years of age and older who weigh at least 40 kg and have moderate-to-severe atopic dermatitis.

    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyEbglyss (lebrikizumab-lbkz) Coverage for Moderate-to-Severe Atopic Dermatitis
    Policy CodePolicy N/A
    Change TypeAdministrative line-of-business revision
    Effective DateJuly 1, 2026
    Next Review DateN/A
    Key ActionSubmit the HMSA prior authorization fax form for Ebglyss.
    SourceLink
    POLICY UPDATE CHANGES

    The QUEST line of business was removed from the policy effective 07/01/2026.

    12+ yearsMinimum member age
    40 kgMinimum member weight
    4 monthsInitial authorization
    12 monthsReauthorization

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    10% BSA
    Affected body-surface-area threshold

    Coverage Criteria

    Initial Therapy

    Authorization of 4 months may be granted when ALL of the following are met:

    ALL of the following

    • Member is 12 years of age or older.≥ 12 years
    • Member weighs at least 40 kg.≥ 40 kg
    • ONE of the following treatment pathways

      • Member previously received a biologic indicated for moderate-to-severe atopic dermatitis in the past 180 days (e.g., Adbry, Dupixent, or Nemluvio).Past 180 days
      • Member previously received a systemic targeted synthetic drug indicated for moderate-to-severe atopic dermatitis in the past 180 days (e.g., Cibinqo or Rinvoq).Past 180 days
      • Moderate-to-severe atopic dermatitis pathway

        • Affected area requirement

          • Affected body surface is greater than or equal to 10% body surface area.≥ 10% body surface area
          • A crucial body area is affected, including the hands, feet, face, neck, scalp, genitals/groin, or intertriginous areas.
        • ONE of the following treatment requirements

          • Member had an inadequate treatment response to two of the following treatments in the past 180 days: a high-potency or super-high-potency topical corticosteroid (see Appendix), a topical calcineurin inhibitor, a topical JAK inhibitor, or a topical PDE-4 inhibitor.Inadequate response to 2 treatments; past 180 days

    Continuation and Reauthorization

    Continuation and reauthorization may be granted when the applicable pathway below is met:

    ONE of the following pathways

    • No previous authorization or precertification

      • Member has no previous authorization or precertification. All members, including new members and members currently receiving treatment without prior authorization, must meet the Initial Therapy coverage criteria.
    • Reauthorization

      • Member is 12 years of age or older.≥ 12 years
      • Member weighs at least 40 kg.≥ 40 kg

    The member cannot use the requested medication concomitantly with any other biologic drug or targeted synthetic drug for the same indication.

    Coverage Parameters

    Minimum Age
    Minimum age12 years of age or older
    Applies toInitial authorization and reauthorization
    Covered conditionModerate-to-severe atopic dermatitis
    Minimum Weight
    Minimum weightAt least 40 kg
    Applies toInitial authorization and reauthorization
    Covered treatmentEbglyss for moderate-to-severe atopic dermatitis

    Provider Requirements and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required before Ebglyss treatment can be initiated or continued. Submit the request using the HMSA fax form available on the HMSA medical policy website.

    Billing Rule

    Specialist Prescribing or Consultation Required

    Ebglyss must be prescribed by, or in consultation with, a dermatologist or allergist/immunologist.

    Step Therapy

    Prior Biologic or Targeted Synthetic Therapy

    Policy Background

    Ebglyss (lebrikizumab-lbkz) is covered for adults and pediatric patients 12 years of age and older who weigh at least 40 kg and have moderate-to-severe atopic dermatitis. Coverage applies when the disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Ebglyss may be used with or without topical corticosteroids.

    Initial Therapy Criteria

    Initial Therapy Criteria

    Initial authorization may be granted for 4 months when all member eligibility requirements are met and either the prior systemic-therapy pathway or the disease-severity/topical-therapy pathway is satisfied.

    Member eligibility: Member is 12 years of age or older and weighs at least 40 kg.age >= 12 years; weight >= 40 kg

    Initial therapy pathways

    • Prior systemic therapy pathway: Member previously received a biologic indicated for moderate-to-severe atopic dermatitis, such as Adbry, Dupixent, or Nemluvio, or a systemic targeted synthetic drug such as Cibinqo or Rinvoq, within the past 180 days.within past 180 days
    • Disease severity and topical therapy pathway

    Continuation Criteria

    Continuation Therapy Criteria

    Continuation therapy is available under one of the following pathways.

    Continuation coverage

    • No previous authorization: Member has no previous authorization, including a new member or a member currently receiving treatment without prior authorization, and meets all criteria in the coverage criteria section.
    • Reauthorization: Member is 12 years of age or older, weighs at least 40 kg, was previously authorized by HMSA/CVS, and achieves or maintains a positive clinical response.age >= 12 years; weight >= 40 kg; authorization duration 12 months

      Positive clinical response is evidenced by low disease activity, such as clear or almost clear skin, or improvement in signs and symptoms of atopic dermatitis, such as redness, itching, or oozing/crusting.

    Step Therapy Requirements

    StepRequirementDetails
    1Meet at least one qualifying treatment-history pathwayPreviously received a biologic indicated for moderate-to-severe atopic dermatitis (such as Adbry, Dupixent, or Nemluvio) or a systemic targeted synthetic drug (such as Cibinqo or Rinvoq) within the past 180 days; or had an inadequate response within the past 180 days to two of the following: a high- or super-high-potency topical corticosteroid, topical calcineurin inhibitor, topical JAK inhibitor, or topical PDE-4 inhibitor. If use of all four topical therapy categories is not advisable, that alternative also satisfies the topical-therapy pathway.
    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyEbglyss (lebrikizumab-lbkz) Coverage for Moderate-to-Severe Atopic Dermatitis
    Policy CodePolicy N/A
    Change TypeAdministrative line-of-business revision
    Effective DateJuly 1, 2026
    Next Review DateN/A
    Key ActionSubmit the HMSA prior authorization fax form for Ebglyss.
    SourceLink
    On This Page
    Coverage CriteriaCoverage ParametersProvider Requirements and Denial RisksPolicy BackgroundInitial Therapy CriteriaContinuation CriteriaStep Therapy Requirements
    Use of a high-potency or super-high-potency topical corticosteroid, topical calcineurin inhibitor, topical JAK inhibitor, and topical PDE-4 inhibitor is not advisable for the member, such as due to contraindications, prior intolerances, or potency not appropriate for the member's age.
    Member was previously authorized by HMSA/CVS.
  1. Member achieves or maintains a positive clinical response, as evidenced by low disease activity (i.e., clear or almost clear skin) or improvement in signs and symptoms of atopic dermatitis (e.g., redness, itching, or oozing/crusting).
  2. Affected Body Surface Area
    Body-surface-area thresholdAffected body surface must be greater than or equal to 10%
    ExceptionThe 10% threshold does not apply when crucial body areas are affected
    Crucial body areasHands, feet, face, neck, scalp, genitals/groin, and intertriginous areas
    Prior Systemic Therapy Lookback
    Lookback periodWithin the past 180 days
    Qualifying treatmentA biologic indicated for moderate-to-severe atopic dermatitis or a systemic targeted synthetic drug
    ExamplesAdbry, Dupixent, Nemluvio, Cibinqo, or Rinvoq
    Initial Authorization Duration
    Initial authorization4 months
    EligibilityMember must be at least 12 years old and weigh at least 40 kg
    Coverage pathwayPrior qualifying systemic therapy or the disease-severity and topical-therapy pathway must be met
    Reauthorization Duration
    Reauthorization12 months
    Prior authorizationMember must have been previously authorized by HMSA/CVS
    Clinical responseMember must achieve or maintain a positive clinical response, such as clear or almost clear skin or improvement in redness, itching, or oozing/crusting

    One initial-authorization pathway requires documentation that the member received a biologic or systemic targeted synthetic drug indicated for moderate-to-severe atopic dermatitis within the past 180 days.

    • Examples include biologics such as Adbry, Dupixent, or Nemluvio and targeted synthetic drugs such as Cibinqo or Rinvoq.
    Step Therapy

    Topical Therapy Trial or Clinical Unsuitability

    When the prior biologic or targeted synthetic therapy pathway is not used, document inadequate response to two qualifying topical therapies within the past 180 days, or explain why all specified topical therapies are clinically unsuitable.

    • Qualifying therapies include a high- or super-high-potency topical corticosteroid, topical calcineurin inhibitor, topical JAK inhibitor, or topical PDE-4 inhibitor.
    • Clinical unsuitability may include contraindications, prior intolerance, or potency that is not appropriate for the member's age.
    Documentation Required

    Document Disease Extent

    For initial requests, submit chart notes or medical records documenting the affected areas and body surface area, where applicable.

    • Coverage requires affected body surface of at least 10% or involvement of crucial body areas, including the hands, feet, face, neck, scalp, genitals/groin, or intertriginous areas.
    Documentation Required

    Document Prior Treatment History

    For initial requests, submit documentation of previous medications and treatment trials, including dosage, duration, and response to therapy. If a therapy was not advisable, document the clinical reason for avoiding it.

    • Documentation may include chart notes, medical records, or claims history.
    • Include prior topical calcineurin inhibitors, topical corticosteroids, topical JAK inhibitors, topical PDE-4 inhibitors, and biologic or targeted synthetic drugs, as applicable.
    Documentation Required

    Document Positive Clinical Response

    For continuation or reauthorization requests, submit chart notes or medical records supporting a positive clinical response to treatment.

    • Response may be evidenced by low disease activity, such as clear or almost clear skin, or improvement in redness, itching, oozing, or crusting.
    Denial Risk

    Age or Weight Requirement Not Met

    Coverage is not available when the member is younger than 12 years or weighs less than 40 kg.

    • The age and weight requirement applies to both initial authorization and reauthorization.
    Denial Risk

    Initial Clinical Criteria Not Met

    An initial request may be denied when the member does not meet an applicable clinical pathway. This includes failure to document qualifying prior biologic or systemic targeted synthetic therapy, or failure to meet the required disease-extent and topical-treatment criteria.

    • The qualifying prior biologic or systemic targeted synthetic drug must have been used within the past 180 days.
    • The alternative pathway requires affected body surface of at least 10% or crucial body-area involvement, plus inadequate response to two qualifying topical therapies within the past 180 days or clinical unsuitability of the specified topical therapies.
    Denial Risk

    Insufficient Documentation

    Requests may be denied or delayed when required treatment documentation is missing or insufficient. Ensure initial requests include disease extent and prior-treatment evidence, and continuation requests include documentation of positive clinical response.

    • Initial documentation should include affected areas, body surface area where applicable, prior medications, dosage, duration, response, or clinical reasons therapy was avoided.
    • Continuation documentation should support low disease activity or improvement in atopic dermatitis signs and symptoms.
    Denial Risk

    Unqualified Prescriber

    A request may be denied when the prescriber is not a dermatologist or allergist/immunologist and there is no documented consultation with one of these specialists.

    Denial Risk

    Concomitant Same-Indication Therapy

    Ebglyss cannot be used concomitantly with another biologic drug or targeted synthetic drug for the same indication.

    • Document that the requested medication will not be administered concurrently with another biologic or targeted synthetic drug for atopic dermatitis.
  3. Topical therapy requirement

    • Inadequate response to topical therapies: Member had an inadequate treatment response to two of the following topical therapy categories within the past 180 days: a high-potency or super-high-potency topical corticosteroid, topical calcineurin inhibitor, topical JAK inhibitor, or topical PDE-4 inhibitor.2 of 4 categories; within past 180 days
    • Topical therapies not advisable: Use of a high-potency or super-high-potency topical corticosteroid, topical calcineurin inhibitor, topical JAK inhibitor, and topical PDE-4 inhibitor is not advisable for the member, such as because of contraindications, prior intolerances, or potency not appropriate for the member's age.all 4 categories